Mizuho Downgrades Phillips Edison to Neutral, Announces $35 Price Target

Mizuho analyst Haendel St. Juste downgrades Phillips Edison (NASDAQ:PECO) from Buy to Neutral and announces $35 price target.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Mizuho analyst Haendel St. Juste downgrades Phillips Edison (NASDAQ:PECO) from Buy to Neutral and announces $35 price target.

News

Population Health Investment Will Redeem Public Shares At ~$10.09/Share, Will Not Consummate Initial Business Combination

By Michael Horton

November 18, 5:17 PM

Population Health Investment Co., Inc. (NASDAQ:PHIC), a special purpose acquisition company (the "Company"), today announced that it will redeem all of its outstanding Class A ordinary shares, par

PHIC

Nektar And Collaborators Announce Preclinical Publication Of Data For NKTR-255 And Its Observed Improvement Of NK Cell Function In Multiple Myeloma

By Benzinga Newsdesk

August 16, 8:33 AM

Nektar Therapeutics (NASDAQ:NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel

NKTR

Teradata Q2 Adj. EPS $0.74 Beats $0.46 Estimate, Sales $491.00M Beat $475.37M Estimate

By Benzinga Newsdesk

August 5, 5:13 PM

Teradata (NYSE:TDC) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.46 by 60.87 percent. This is a 208.33 percent increase over earnings of $0.24 per share from the same

TDC

ContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Study

By Vandana Singh

December 20, 10:35 AM

ContraFect Corporation (NASDAQ:CFRX) has announced the database lock of its Phase 3 DISRUPT study of exebacase in patients with Staph…

CFRX

Mizuho Downgrades Phillips Edison to Neutral, Announces $35 Price Target

Related Posts

Population Health Investment Will Redeem Public Shares At ~$10.09/Share, Will Not Consummate Initial Business Combination

Nektar And Collaborators Announce Preclinical Publication Of Data For NKTR-255 And Its Observed Improvement Of NK Cell Function In Multiple Myeloma

Teradata Q2 Adj. EPS $0.74 Beats $0.46 Estimate, Sales $491.00M Beat $475.37M Estimate

ContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Study